Infectious Disease PHARMACOTHERAPY Self Assessment

Lea S. Eiland, PharmD, BCPS, FASHP, FPPAG

Clinical Professor and Associate Department Head Auburn University Harrison School of Pharmacy Auburn, Alabama

Diane B. Ginsburg, PhD, RPh, FASHP

Clinical Professor Assistant Dean for Student Affairs College of Pharmacy Health Outcomes and Pharmacy Practice Division The University of Texas at Austin Austin, Texas



Any correspondence regarding this publication should be sent to the publisher, American Society of Health-System Pharmacists, 7272 Wisconsin Avenue, Bethesda, MD 20814, attention: Special Publishing.

The information presented herein reflects the opinions of the contributors and advisors. It should not be interpreted as an official policy of ASHP or as an endorsement of any product.

Because of ongoing research and improvements in technology, the information and its applications contained in this text are constantly evolving and are subject to the professional judgment and interpretation of the practitioner due to the uniqueness of a clinical situation. The editors and ASHP have made reasonable efforts to ensure the accuracy and appropriateness of the information presented in this document. However, any user of this information is advised that the editors and ASHP are not responsible for the continued currency of the information, for any errors or omissions, and/or for any consequences arising from the use of the information in the document in any and all practice settings. Any reader of this document is cautioned that ASHP makes no representation, guarantee, or warranty, express or implied, as to the accuracy and appropriateness of the information contained in this document and specifically disclaims any liability to any party for the accuracy and/or completeness of the material or for any damages arising out of the use or non-use of any of the information contained in this document.

Director, Special Publishing: Jack Bruggeman

Acquisitions Editor: Robin Coleman
Editorial Project Manager: Ruth Bloom
Production Manager: Kristin Eckles

Cover & Page Design: David Wade and Carol Barrer

Library of Congress Cataloging-in-Publication Data

Eiland, Lea S., author.

Infectious disease pharmacotherapy self assessment / Lea S. Eiland, Diane B. Ginsburg.

p.; cm.

Includes bibliographical references and index.

ISBN 978-1-58528-492-4 (alk. paper)

I. Ginsburg, Diane B., author. II. American Society of Health-System Pharmacists, issuing body. III. Title.

[DNLM: 1. Communicable Diseases--drug therapy--Case Reports. 2. Communicable Diseases--drug therapy--

Problems and Exercises. 3. Communicable Diseases--diagnosis--Case Reports. 4.

Communicable Diseases--diagnosis--Problems and Exercises. WC 18.2] RM301 615.1--dc23

2015012112

©2015, American Society of Health-System Pharmacists, Inc. All rights reserved.

No part of this publication may be reproduced or transmitted in any form or by any means, electronic or mechanical, including photocopying, microfilming, and recording, or by any information storage and retrieval system, without written permission from the American Society of Health-System Pharmacists.

ASHP is a service mark of the American Society of Health-System Pharmacists, Inc.; registered in the U.S. Patent and Trademark Office.

ISBN: 978-1-58528-492-4

DEDICATION

We dedicate this self-assessment book to those students and practitioners who participate in lifelong self-learning and strive to do better for their patients.

CONTENTS

PREFACE	
ACKNOWLEDGMENTS	
PART I. CASES	
SECTION 1. BONE AND JOINT/SKIN AND SOFT TISSUE	1
1.1 Acute Osteomyelitis Level 1	1
1.2 Skin and Soft Tissue Infection Level 2	3
1.3 Diabetic Foot Infection Level 3	7
SECTION 2. GASTROINTESTINAL AND CENTRAL NERVOUS SYSTEM	9
1.4 Gastrointestinal Infection—Clostridium Difficile Level 1	9
1.5 Gastrointestinal Infection—Shigella Level 2	13
1.6 Meningitis Level 2	17
1.7 Neurosyphilis Level 3	21
SECTION 3. PULMONARY	23
1.8 Acute Otitis Media Level 1	
1.9 Acute Otitis Externa Level 1	25
1.10 Community-Acquired Pneumonia Level 1	27
1.11 Ventilator-Associated Pneumonia Level 2	31
1.12 Influenza Level 2	35
1.13 Tuberculosis Level 3	37
1.14 Healthcare-Associated Pneumonia Level 3	39
SECTION 4. BACTEREMIA, ENDOCARDITIS, AND SEPSIS	41
1.15 Neonatal Sepsis Level 1	
1.16 Infective Endocarditis—Viridans Group Streptococci Level 1	43
1.17 Catheter-Related Bloodstream Infection—Antibiotic Resistance Level 2	45
1.18 Infective Endocarditis—Staphylococcus Level 2	49
1.19 Bacteremia, Gram Positive Level 2	51
1.20 Bacteremia, Gram Negative Level 3	55
1.21 Severe Sepsis Level 3	57
1.22 Septic Shock Level 3	59
SECTION 5. INTRA-ABDOMINAL INFECTIONS AND GENITOURINARY	61
1.23 Complicated Urinary Tract Infection—Geriatric Level 1	61
1.24 Urinary Tract Infection—Pediatric Level 1	65
1.25 Uncomplicated Urinary Tract Infection Level 2	69
1.26 Intra-abdominal Infection Level 3	73
SECTION 6. HIV INFECTION	77
1.27 HIV—Pneumocystis Jirovecii Pneumonia Level 2	
1.28 HIV Medication Management Level 2	79

CONTENTS

SECTION 7. FUNGAL INFECTION	
1.29 Vulvovaginal Candidiasis Level 1	
1.30 Disseminated Candidiasis Level 3	83
SECTION 8. TICK-BORNE INFECTION	85
1.31 Lyme Disease Level 1	85
SECTION 9. SEXUALLY TRANSMITTED DISEASES	87
1.32 Neisseria Gonorrhea Level 2	87
1.33 Genital Herpes Level 3	89
PART II. QUESTIONS & ANSWERS	
SECTION 1. BONE AND JOINT/SKIN AND SOFT TISSUE	93
2.1 Acute Osteomyelitis Level 1	93
2.2 Skin and Soft Tissue Infection Level 2	97
2.3 Diabetic Foot Infection Level 3	101
SECTION 2. GASTROINTESTINAL AND CENTRAL NERVOUS SYSTEM	103
2.4 Gastrointestinal Infection—Clostridium Difficile Level 1	103
2.5 Gastrointestinal Infection—Shigella Level 2	107
2.6 Meningitis Level 2	111
2.7 Neurosyphilis Level 3	115
SECTION 3. PULMONARY	117
2.8 Acute Otitis Media Level 1	117
2.9 Acute Otitis Externa Level 1	119
2.10 Community-Acquired Pneumonia Level 1	121
2.11 Ventilator-Associated Pneumonia Level 2	125
2.12 Influenza Level 2	129
2.13 Tuberculosis Level 3	131
2.14 Healthcare-Associated Pneumonia Level 3	135
SECTION 4. BACTEREMIA, ENDOCARDITIS, AND SEPSIS	137
2.15 Neonatal Sepsis Level 1	137
2.16 Infective Endocarditis—Viridans Group Streptococci Level 1	139
$2.17\ Catheter\text{-Related Bloodstream Infection} - Antibiotic\ Resistance\ \mid\ Level\ 2$	141
2.18 Infective Endocarditis—Staphylococcus Level 2	145
2.19 Bacteremia, Gram Positive Level 2	149
2.20 Bacteremia, Gram Negative Level 3	151
2.21 Severe Sepsis Level 3	153
2.22 Septic Shock Level 3	155

CONTENTS

SECTION 5. INTRA-ABDOMINAL INFECTIONS AND GENITOURINARY	157
2.23 Complicated Urinary Tract Infection—Geriatric Level 1	157
2.24 Urinary Tract Infection—Pediatric Level 1	161
2.25 Uncomplicated Urinary Tract Infection Level 2	163
2.26 Intra-abdominal Infection Level 3	167
SECTION 6. HIV INFECTION	169
2.27 HIV—Pneumocystis Jirovecii Pneumonia Level 2	169
2.28 HIV Medication Management Level 2	171
SECTION 7. FUNGAL INFECTION	173
2.29 Vulvovaginal Candidiasis Level 1	173
2.30 Disseminated Candidiasis Level 3	175
SECTION 8. TICK-BORNE INFECTION	177
2.31 Lyme Disease Level 1	177
SECTION 9. SEXUALLY TRANSMITTED DISEASES	179
2.32 Neisseria Gonorrhea Level 2	179
2.33 Genital Herpes Level 3	181
APPENDIX: COMMON MEDICAL TERMINOLOGY AND ABBREVIATIONS	183
INDEX	189

PREFACE

Every patient in his or her lifetime will develop an infectious disease just as pharmacists encounter infectious diseases in various populations daily. The patient may be presenting with a primary infectious disease process or with multiple problems and the added complication of an infectious process requiring specialized care and development of an appropriate treatment plan. The management of infectious diseases requires keen clinical skills and knowledge. *Infectious Disease Pharmacotherapy Self Assessment* is designed to provide clinicians with patient-specific, case-based learning for students, new practitioners, and advanced level practitioners. This textbook provides practitioners with infectious disease pharmacotherapy knowledge to care for pediatric and adult patients in various healthcare settings. Other infectious disease topics such as stewardship, antibiograms, and vaccinations are also assessed. The cases represent a range of clinical situations of varying complexity and include corresponding self-assessment questions and answers.

Each case is based on a real patient and designed to include clinical data necessary to develop a treatment plan for all aspects of care, including assessing patient-specific parameters used in the diagnosis of the infectious process; developing goals and clinical outcomes; preventing or managing comorbidities; and monitoring parameters and relevant patient/ caregiver education. The intent of each case is to develop skills in identifying clinical relative patient and disease information to support a specific diagnosis and design an appropriate treatment and monitoring plan for the management of the infectious disease. The self-assessment cases may be useful for didactic coursework and preparation for both introductory and advanced pharmacy practice experiences (IPPEs/APPEs). The cases may also be valuable prior to starting a PGY1 or PGY2 residency rotation or a position focused in infectious diseases. The casebook's varying levels of difficulty allow further self-assessment after attainment of basic knowledge and skills.

The casebook is divided into two parts: patient cases (Part I) and self-assessment questions and answers (Part II). The contributors provide a variety of patient cases encountered in their respective practices. Cases are designed as level 1 (beginner), level 2 (intermediate), or level 3 (advanced), which allows the casebook to be a resource for students, residents, and practitioners. Sources are provided for each disease state case so that practitioners can use the primary source for additional information and/or clarification. Current practice guidelines are referenced including the CDC's Sexually Transmitted Diseases Treatment Guidelines, 2015 and the DHHS's Guidelines for the Use of Antiretroviral Agents in HIV-1-Infected Adults and Adolescents (April 2015). The casebook incorporates many situations to address managing a patient with an infectious disease and handling other infectious disease issues (e.g., stewardship, infection control, etc.). The intent of the editors and contributors is to provide opportunities for self-assessment through practice and knowledge application, thereby contributing to the development of students and practitioners in managing an infectious process.

Lea S. Eiland Diane B. Ginsburg

ACKNOWLEDGMENTS

We would like to acknowledge the following original case writers and section editors from the infectious disease section of *PharmPrep: ASHP's NAPLEX® Review, Fourth Edition*. Although cases have been changed and updated, their initial work is appreciated.

Jason Cota, PharmD, MSc

Edward H. Eiland, III, PharmD, MBA, BCPS (AQ-ID), FASHP

Lea S. Eiland, PharmD, BCPS, FASHP, FPPAG

Sharon Erdman, PharmD

John Esterly, PharmD, BCPS (AQ-ID)

Marianna Fedorenko, PharmD

Alexandria Garavaglia-Wilson, PharmD

E. Kelly Hester, PharmD, BCPS, AAHIVP

Karl Madaras-Kelly, PharmD, MPH

Catherine Oliphant, PharmD

Celtina K. Reinert, PharmD

David J. Ritchie PharmD, FCCP, BCPS (AQ-ID)

Michael P. Rivey, MS, BCPS, FASHP

Marc Scheetz, PharmD, MSc, BCPS (AQ-ID)

Amelia Sofjan, PharmD, BCPS

Collin N. Verheyden, PharmD, BCPS

Katie Vuong, PharmD

Nancy Toedter Williams, PharmD, BCPS, BCNSP, FASHP

We greatly appreciate the time and efforts of Collin N. Verheyden, PharmD, BCPS, for his review of each case. His comments and suggestions strengthened our material.

In addition, we would like to thank Edward H. Eiland, III, PharmD, MBA, BCPS (AQ-ID), FASHP, for his assistance in answering questions and providing advice about various infectious disease topics when selecting and designing each case.

Lastly, a sincere thank-you to the ASHP Special Publications staff who listened to our ideas and assisted in the development of this self-assessment textbook. We are proud to be part of the self-assessment series to assist students and practitioners in strengthening their patient care knowledge related to infectious diseases.

PART 1 | CASES

	oft Tissue
1.	1 Acute Osteomyelitis Level 1 1
1.	2 Skin and Soft Tissue Infection Level 2 3
1	.3 Diabetic Foot Infection Level 3 7
C	ection 2. Gastrointestinal and Eentral Nervous System9
1	.4 Gastrointestinal Infection—Clostridium Difficile Level 1
	1.5 Gastrointestinal Infection—Shigella Level 2
	1.6 Meningitis Level 2 17
	1.7 Neurosyphilis Level 321
	Section 3. Pulmonary
	1.8 Acute Otitis Media Level 123
	1.9 Acute Otitis Externa Level 125
	1.10 Community-Acquired Pneumonia Level 127
	1.11 Ventilator-Associated Pneumonia Level 231
	1.12 Influenza Level 2
	1.13 Tuberculosis Level 3 37
1.14 Healthcare-Associated	Pneumonia Level 3
	litis, and Sepsis41
	41
	Group Streptococci Level 1
	fection—Antibiotic Resistance Level 2 45
	coccus Level 2
•	1 2
	/el 355
·	57
22 Septic Shock Level 3	59
	ns and Genitourinary61 ract Infection—Geriatric Level 161

PART 1 | CASES

1.24 Urinary Tract Infection—Pediatric Level 1	65
1.25 Uncomplicated Urinary Tract Infection Level 2	69
1.26 Intra-abdominal Infection Level 3	73
Section 6. HIV Infection	77
1.27 HIV—Pneumocystis Jirovecii Pneumonia Level 2	77
1.28 HIV Medication Management Level 2	79
Section 7. Fungal Infection	81
1.29 Vulvovaginal Candidiasis Level 1	81
1.30 Disseminated Candidiasis Level 3	83
Section 8. Tick-Borne Infection	85
1.31 Lyme Disease Level 1	85
Section 9. Sexually Transmitted Diseases	87
1.32 Neisseria Gonorrhea Level 2	
1.33 Genital Herpes Level 3	89